- Home
- SOHO vs SYBX Comparison
SOHO vs SYBX Comparison
Compare SOHO & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOHO
- SYBX
- Stock Information
- Founded
- SOHO 2004
- SYBX N/A
- Country
- SOHO United States
- SYBX United States
- Employees
- SOHO N/A
- SYBX N/A
- Industry
- SOHO Real Estate Investment Trusts
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- SOHO Real Estate
- SYBX Health Care
- Exchange
- SOHO Nasdaq
- SYBX Nasdaq
- Market Cap
- SOHO 15.4M
- SYBX 13.6M
- IPO Year
- SOHO 2004
- SYBX N/A
- Fundamental
- Price
- SOHO $0.87
- SYBX $1.24
- Analyst Decision
- SOHO Hold
- SYBX
- Analyst Count
- SOHO 1
- SYBX 0
- Target Price
- SOHO $1.50
- SYBX N/A
- AVG Volume (30 Days)
- SOHO 43.0K
- SYBX 7.4K
- Earning Date
- SOHO 08-12-2025
- SYBX 08-07-2025
- Dividend Yield
- SOHO N/A
- SYBX N/A
- EPS Growth
- SOHO N/A
- SYBX N/A
- EPS
- SOHO N/A
- SYBX 0.21
- Revenue
- SOHO $182,158,199.00
- SYBX N/A
- Revenue This Year
- SOHO $13.93
- SYBX N/A
- Revenue Next Year
- SOHO N/A
- SYBX N/A
- P/E Ratio
- SOHO N/A
- SYBX $5.68
- Revenue Growth
- SOHO 3.11
- SYBX N/A
- 52 Week Low
- SOHO $0.59
- SYBX $0.90
- 52 Week High
- SOHO $1.54
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- SOHO 44.07
- SYBX 54.75
- Support Level
- SOHO $0.94
- SYBX $1.18
- Resistance Level
- SOHO $1.04
- SYBX $1.27
- Average True Range (ATR)
- SOHO 0.09
- SYBX 0.05
- MACD
- SOHO -0.02
- SYBX -0.00
- Stochastic Oscillator
- SOHO 18.52
- SYBX 58.33
About SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.